The European Commission (EC) has approved Novo Holdings’ acquisition of Catalent and the subsequent related acquisition of three Catalent manufacturing sites from Novo Holdings by Novo Nordisk, Novo Nordisk announced on Dec. 6, 2024. Meanwhile, earlier on Dec. 4, 2024, Novavax announced that it signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk for $200 million. Source: Biopharm International 10/12/2024